C07D 285/18
1,2,4-thiadiazines
Official title: 1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
C07D285/18 (1,2,4-thiadiazines) appears on 171 US grants and 145 published applications in this corpus.
Search patents in C07D- Granted patents
- 171
- Published applications
- 145
- Assignees
- 96
- Inventors
- 495
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 3 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 3 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 3 | 0 |
| 1986 | 6 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 4 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 2 |
| 2003 | 7 | 7 |
| 2004 | 1 | 6 |
| 2005 | 4 | 9 |
| 2006 | 6 | 11 |
| 2007 | 8 | 4 |
| 2008 | 3 | 9 |
| 2009 | 10 | 6 |
| 2010 | 5 | 9 |
| 2011 | 4 | 2 |
| 2012 | 4 | 6 |
| 2013 | 6 | 5 |
| 2014 | 4 | 8 |
| 2015 | 4 | 7 |
| 2016 | 8 | 8 |
| 2017 | 9 | 5 |
| 2018 | 5 | 7 |
| 2019 | 4 | 2 |
| 2020 | 1 | 5 |
| 2021 | 3 | 5 |
| 2022 | 2 | 3 |
| 2023 | 2 | 6 |
| 2024 | 5 | 4 |
| 2025 | 6 | 7 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Methods for treating subjects with Prader-Willi syndrome23 Sep 2025US 12,419,895 B1Essentialis, Inc.
- Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome1 Jul 2025US 12,343,348 B2Essentialis, Inc.
- Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms20 May 2025US 12,302,902 B2CorMedix Inc.
- Platform drug delivery system utilizing crystal engineering and theanine dissolution8 Apr 2025US 12,268,783 B2Theaprin Pharmaceuticals Inc.
- Nlrp3 inflammasome inhibitors and uses thereof2 Jul 2026US 2026/0184704 A1Insilico Medicine IP Limited
- Nlrp3 inflammasome inhibitors and uses thereof25 Jun 2026US 2026/0176261 A1Insilico Medicine IP Limited
- Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms11 Dec 2025US 2025/0374925 A1CorMedix Inc.
- Novel atp-sensitive potassium channel potentiators, their preparation and use27 Nov 2025US 2025/0360142 A1Rhythm Pharmaceuticals, Inc.
- Methods for treating subjects with prader-willi syndrome18 Sep 2025US 2025/0288593 A1Essentialis, Inc.
Most cited
By later US patents
- Quinoline derivatives as PI3 kinase inhibitors178US 8,138,347 B2GlaxoSmithKline LLC · 2012
- Compositions and methods for inhibition of the JAK pathway88US 7,491,732 B2Rigel Pharmaceuticals, Inc. · 2009
- Substituted aminomethyltetralins and their heterocyclic analogues81US 5,137,901 ABayer Aktiengesellschaft · 1992
- Salts of potassium ATP channel openers and uses thereof69US 7,572,789 B2Essentialis, Inc. · 2009
- Benzo thiadiazine matrix metalloproteinase inhibitors40US 6,656,932 B2Warner-Lambert Company · 2003